Trials / No Longer Available
No Longer AvailableNCT01956253
Single Subject Neratinib in Bladder Cancer (NRR)
Single Subject Neratinib in Bladder Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neratinib | 240 mg orally once daily |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-09-01
- Completion
- 2014-06-01
- First posted
- 2013-10-08
- Last updated
- 2017-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01956253. Inclusion in this directory is not an endorsement.